Is it possible to protect the preterm infant brain and to decrease later neurodeveloppemental disabilities?;Est-il possible de protéger le cerveau de l'enfant né prématuré et de diminuer le taux de séquelles neuro-développementales ?

Archives de Pediatrie

Volumn 15, Issue SUPPL. 1, 2008, Pages

  Marret, S ^a   Foix l'Helias L ^b   Ancel, P Y ^b   Kaminski, M ^b   Larroque, B ^b   Marcou Labarre, A ^a   Laudenbach, V ^a  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANESTHETIC AGENT; BETAMETHASONE; BRAIN DERIVED NEUROTROPHIC FACTOR; CAFFEINE; CORTICOSTEROID; DEXAMETHASONE; ERYTHROPOIETIN; ETAMSYLATE; INDOMETACIN; MAGNESIUM SULFATE; NITRIC OXIDE; PHENOBARBITAL; PLACEBO; RECOMBINANT ERYTHROPOIETIN; UTERUS SPASMOLYTIC AGENT;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN DAMAGE; BRAIN DEVELOPMENT; BRAIN PROTECTION; CEREBRAL PALSY; CHILD BEHAVIOR; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DEVELOPMENTAL DISORDER; EARLY INTERVENTION; ENCEPHALOMALACIA; HUMAN; IMMATURITY; INFANT MORTALITY; LOW DRUG DOSE; MORTALITY; MOTOR DYSFUNCTION; MYELINATION; NEUROLOGIC DISEASE; PERINATAL PERIOD; PREMATURITY; PRENATAL CARE; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME; WHITE MATTER;

ANIMALS; BRAIN DAMAGE, CHRONIC; DEVELOPMENTAL DISABILITIES; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; NEUROPROTECTIVE AGENTS;

EID: 52349097488     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-693X(08)73945-9     Document Type: Article

References (52)

1. Marlow N., Wolke D., Bracewell M.A., et al. Neurologic and developmental disability at six years of age after extremely preterm birth. N Engl J Med 352 (2005) 3264-3272
2. Marret S., Ancel P.Y., Marpeau L., et al. Neonatal and 5-year outcomes after birth at 30-34 weeks' gestation: the EPIPAGE cohort study. Obstet Gynecol 110 (2007) 72-80
3. Larroque B., Ancel P.Y., Marret S., et al. Neurodevelopmental disabilities and use of special care needs of 5-year-old children born before 33 weeks' gestation: the EPIPAGE study. Lancet 371 (2008) 813-820
4. Expertise collective de l'INSERM. Déficiences et handicaps d'origine périnatale. Dépistage et prise en charge. Paris. Editions Inserm; 2004.
5. Saliba E., and Marret S. Cerebral white matter damage in the preterm infant: pathophysiology and risk factors. Semin Neonatol 6 (2001) 121-133
6. Gluckman P.D., Pinal C.S., and Gunn A.J. Hypoxic-ischemic brain injury in the newborn: pathophysiology and potential strategies for intervention. Semin Neonatol 6 (2001) 109-120
7. Marret S., Mukendi R., Gadisseux J.F., et al. Effect of ibotenate on brain development: an excitotoxic mouse model of microgyria and posthypoxic-like lesions. J Neuropathol Exp Neurol 54 (1995) 358-370
8. Billiard S.S., Haynes R., Folkerth R.D., et al. Development of microglia in the cerebral white matter of the human fetus and infant. J Comp Neurol 497 (2006) 199-208
9. Ballabh P., Xu H., Hu F., et al. Angiogenic inhibition reduces germinal matrix hemorrhage. Nat Med 13 (2007) 477-485
10. Dupont E., Hanganu I.L., Kilb W., et al. Rapid developmental switch in the mechanisms driving early cortical columnar networks. Nature 439 (2006) 79-83
11. Billiards SS, Haynes RL, Folkerth RD, et al. Myelin abnormalities without oligodendrocyte loss in periventricular leukomalacia. Brain Pathol 2007; doi: 10.1111/j.1750-3639.2007.00107.x.
12. Tahraoui S.L., Marret S., Bodénant C., et al. Central role of microglia in neonatal excitotoxic lesions of the murine periventricular white matter. Brain Pathol 11 (2001) 56-71
13. McQuillen P.S., Sheldin R.A., Shatz C.J., et al. Selective vulnerability of subplate neurons after early neonatal hypoxia-ischemia. J Neurosci 23 (2003) 3308
14. Karadottir R., and Attwell D. Neurotransmitter receptors in the life and death of oligodendrocytes. Neuroscience 145 (2007) 1426-1438
15. Pocock J.M., and Kettenmann H. Neurotransmitter receptors on microglia. Trends Neurosci 30 (2007) 527-535
16. Olney J.W., Wozniak D.F., Jevtovic-Todorovic V., et al. Drug-induced apoptotic neurodegeneration in the developing brain. Brain Pathol 12 (2002) 488-498
17. Laudenbach V., Fontaine R., Medja F., et al. Vascular Endothelial Growth Factor is involved in the neuroprotection elicited by hypoxic preconditioning in the developing mouse brain. Neurobiol Dis 26 (2007) 243-252
18. Leviton A., and Gressens P. Neuronal damage accompanies perinatal white-matter damage. Trends Neurosci 30 (2007) 473-478
19. Crowther C.A., Hiller J.E., and Doyle L.W. Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database Syst Rev 4 (2002) CD001060
20. Marret S., Doyle L.W., Crowther C.A., et al. Antenatal magnesium sulphate neuroprotection in the preterm infant. Semin Fetal Neonatal Med 12 (2007) 311-317
21. Crowther C.A., Hiller J.E., Doyle L.W., et al. Effect of magnesium sulfate given for neuroprotection before preterm birth. A randomized controlled trial. JAMA 290 (2003) 2669-2676
22. Marret S., Marpeau L., Zupan-Simunek V., et al. Magnesium sulphate given before very-preterm birth to protect infant brain: the randomised controlled PREMAG trial. Br J Obstet Gynaecol 114 (2007) 310-318
23. Marret S., Marpeau L., and Bénichou J. Benefit of magnesium sulfate given before very-preterm birth to protect infant brain. Pediatrics 121 (2008) 225-226
24. Doyle L.W., Crowther C.A., Middleton P., et al. Antenatal magnesium sulphate neuroprotection in the preterm infant. Cochrane Database Syst Rev 3 (2007) CD 004661
25. Roberts D., and Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 3 (2006) CD004454
26. Baud O., and Sola A. Corticosteroids in perinatal medicine: how to improve outcomes without affecting the developing brain. Semin Fetal Neonatal Med 12 (2007) 273-279
27. Barrington K.J. The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs. Meta-analysis. BMC Pediatrics 1 (2001) 1
28. Foix-L'Hélias L., Marret S., Ancel P.Y., et al. Impact of the use of antenatal corticosteroids on mortality, cerebral lesions and 5- year neurodevelopmental outcomes of very preterm infants: the EPIPAGE cohort study. Br J Obstet Gynaecol 115 (2008) 275-282
29. Lee H.S., Stoll B.J., McDonald S.A., et al. Neurodevelopmental outcomes of extremely low birth weight infants exposed prenatally to dexamethasone and betamethasone. Pediatrics 121 (2008) 289-296
30. Henderson-Smart D.J., and Davis P.G. Prophylactic methylxanthines for extubation in preterm infants. Cochrane Database Syst Rev 1 (2003) CD000139
31. Desfrère L., Olivier P., Schwendimann, et al. Transient inhibition of astrocytogenesis in developing mouse brain following postnatal caffeine exposure. Pediatr Res 62 (2007) 604-609
32. Back S.A., Craig A., Ling Luo N., et al. Protective effects of caffeine on chronic hypoxia-induced perinatal white matter injury. Ann Neurol 60 (2006) 696-705
33. Bona E., Aden U., Fredholm B.B., et al. The effect of long term caffeine treatment on hypoxic-ischemic brain damage in the neonate. Pediatr Res 38 (1995) 312-318
34. Schmidt B., Roberts R.S., Davis P., et al. Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med 357 (2007) 1893-1902
35. Amin S.B., Sinkin R.A., and Glantz C. Metaanalysis of the effect of antenatal indomethacin on neonatal outcomes. Am J Obstet Gynecol 197 486 (2007) e1-e10
36. Miller S.P., Mayer E.E., Clyman R.I., et al. Prolonged indomethacin exposure is associated with decreased white matter injury detected with magnetic resonance imaging in premature newborns at 24 to 28 weeks'gestation at birth. Pediatrics 117 (2006) 1626-1631
37. Friedman S., Flidel-Rimon O., Steinberg M., et al. Indomethacin tocolysis and white matter injury in preterm infants. J Matern Fetal Neonatal Med 18 (2005) 87-91
38. Fowlie P.W., and Davis P.G. Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database Syst Rev 3 (2002) CD000174
39. Serhan C.N., Hong S., Gronert K., et al. Resolving: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 196 (2002) 1025-1037
40. Askie L.M., Duley L., Henderson-Smart D.J., et al. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 369 (2007) 1791-1798
41. Mestan K., Marks J.D., Hecox K., et al. Neonatal outcome of infants treated with inhaled nitric oxide. N Engl J Med 353 (2005) 23-32
42. Barrington K.J., and Finer N.N. Inhaled nitric oxide for preterm infants: A systematic review. Pediatrics 120 (2007) 1088-1099
43. Gonzalez F.F., McQuillen P., Mu D., et al. Erythopoietin enhances long-term neuroprotection and neurogenesis in neonatal stroke. Dev Neurosci 29 (2007) 321-330
44. Weber A., Dzietko M., Berns, et al. Neuronal damage after moderate hypoxia and erythropoietin. Neurobiol Dis 20 (2005) 594-600
45. Bernaudin M., Nedelec A.S., Divoux D., et al. Normobaric hypoxia induces tolerance to focal permanent cerebral ischemia in association with an increased expression of hypoxia-inducible factor-1 and its target genes, erythropoietin and VEGF, in the adult mouse brain. J Cereb Blood Flow Metab 22 (2002) 393-403
46. Bürher C., Felderhoff-Mueser U., and Wellmann S. Erythropoietin and ischemic conditioning - why two good things may be bad. Acta Paediatr 96 (2007) 787-789
47. Shankaran S., Papile L.A., Wright L.L., et al. The effect of antenatal Phenobarbital therapy on neonatal intracranial hemorrhage. N Engl J Med 338 (1998) 1112-1118
48. Schulte J., Osborne J., Benson J.W.T., et al. Developmental outcome of the use of etamsylate for prevention of periventricular haemorrhage in a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed 90 (2005) F31-F35
49. Lu L.X., Yon J.H., Carter L.B., et al. General anaesthesia activates BDNF-dependant neuroapotosis in the developing brain. Apoptosis 11 (2006) 1603-1615
50. Anand K.J., Hall R.W., Desai N., et al. Effects of analgesia in ventilated preterm neonates: primary outcomes from the NEOPAIN randomized trail. Lancet 363 (2004) 1673-1682
51. Rozé JC, Denizot S, Carbajal R, et al. Prolonged sedation/analgesia and 5-year neurodevelopment outcome in very preterm infants, results from the EPIPAGE cohort. Arch Pediatr Adolesc Med 2008; in press.
52. Stys P.K., and Lipton S.A. White matter NMDA receptors: an unexpected new therapeutic target?. Trends Neurosci 28 (2007) 561-566